- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Sarah B. Goldberg, MD, MPH | Authors
Articles
Considering the Role of Clinical Trials for Patients With Molecularly Altered Lung Cancers
September 03, 2019
Video
Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as EGFR, ALK, BRAF,ROS1, or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.
Treating NSCLC Patients Without an Actionable Oncogenic Driver
May 16, 2017
Video
Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.